Clinical trials: Adenocarcinoma
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other…
- Conditions
- Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT04233567
- Testing
- Infigratinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sameek Roychowdhury
Prostate Cancer
Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods
This study will examine prostate tumor tissue cultures to try to identify genetic abnormalities that contribute to the cause or progression of the disease.
- Trial name
- NCT00022919
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hepatocellular Carcinoma
Randomized Phase II Trial of Chemoembolization and Sorafenib
The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC.
- Trial name
- NCT02908165
- Testing
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Where
- United States
- Sponsor
- Yale University
Lung Adenocarcinoma
Blood Detection of EGFR Mutation For Iressa Treatment
This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.
- Trial name
- Benefit (NCT02282267)
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Renal Cell
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
- Trial name
- NEXTAR (NCT01508364)
- Testing
- Sorafenib (Nexavar, BAY 43-9006)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Bayer
HIV Infections, Hepatitis B
Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population
This is a retrospective study, all HIV-infected individuals followed up at the three designated HIV clinics in Hong Kong with and without HBV and/or HCV co-infection will be included in the analysis.
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma
- Trial name
- NCT03702998
- Where
- Hong Kong
- Volunteers
- 3,900 people
- Sponsor
- Chinese University of Hong Kong
CAR T-Cell Therapy
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects.
- Trial name
- NCT05277987
- Testing
- HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T Cells)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Fifth People's Hospital
Lung Cancer
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that…
- Trial name
- NCT00570401
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Papillary
Active Surveillance of Papillary Thyroid Microcarcinoma
Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imaging modalities, such as CT scan or thyroid…
- Trial name
- NCT02952612
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Dong Jun Lim
Kidney Neoplasms
Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy
Partial nephrectomy is considered the standard treatment for renal tumors smaller than 7 cm. With the evolution of image diagnostic tools and dissemination of its use, smaller tumors are being commonly diagnosed and treated.
- Trial name
- NCT01809119
- Testing
- Partial nephrectomy
- Where
- Brazil
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer
Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00959244
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Nebraska
Metastatic Pancreatic Cancer
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal…
- Trial name
- NCT01839487
- Testing
- PEGPH20, Nab-paclitaxel, Gemcitabine
- Where
- 51 sites in United States
- Volunteers
- 279 people
- Sponsor
- Halozyme Therapeutics
Pancreatic Adenocarcinoma
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with…
- Trial name
- NCT04926467
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor Research Institute
Liver Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01005199
- Testing
- everolimus, sorafenib tosylate
- Where
- 15 sites in Austria, Hungary and 1 more
- Volunteers
- 106 people
- Sponsor
- Swiss Cancer Institute
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04089904
- Testing
- Pembrolizumab Injection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Nausea and Vomiting, Ovarian Brenner Tumor
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
- Conditions
- Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT01275664
- Testing
- Adjuvant Therapy, Aprepitant, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Gynecologic Oncology Group
Colorectal Cancer, Colorectal Adenocarcinoma
Phase 2 Study of DKN-01 in Colorectal Cancer
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and…
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
- Trial name
- DeFianCe (NCT05480306)
- Testing
- DKN-01, FOLFIRI, Bevacizumab
- Where
- 40 sites in United States, Germany and 1 more
- Volunteers
- 188 people
- Sponsor
- Leap Therapeutics, Inc.
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer